Epigenetic findings in autism: New perspectives for therapy

International Journal of Environmental Research and Public Health

Volumn 10, Issue 9, 2013, Pages 4261-4273

  Siniscalco, Dario ^a,b,c   Cirillo, Alessandra ^d   Bradstreet, James Jeffrey ^e   Antonucci, Nicola ^f  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Centre for Autism La Forza del Silenzio   (Italy)

^c Cancellautismo no profit association for autism care   (Italy)

^d INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^e International Child Development Resource Center   (United States)

^f Biomedical Centre for Autism Research and Treatment   (Italy)

Author keywords

Autism; Environmental factors; Gene expression

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; DNA; MESSENGER RNA; NEUROMODULIN; POLYBROMINATED DIPHENYL ETHER; PROTEIN BCL 2;

BIOCHEMISTRY; DNA; DRUG; ENVIRONMENTAL FACTOR; GENE EXPRESSION; METHYLATION; NERVOUS SYSTEM DISORDER; PHYSIOLOGY; STEREOTYPIC BEHAVIOR;

AUTISM; BCL 2 GENE; CLINICAL FEATURE; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; DNA MODIFICATION; DNA TRANSCRIPTION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; ENZYME PHOSPHORYLATION; EPIGENETICS; FRAGILE X SYNDROME; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; HISTONE MODIFICATION; HUMAN; MOLECULAR DYNAMICS; NUTRITIONAL DEFICIENCY; RETINOIC ACID RECEPTOR RELATED ORPHAN RECEPTOR GENE; RETT SYNDROME; REVIEW; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION;

ANIMALS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; ENVIRONMENT; EPIGENESIS, GENETIC; HISTONES; HUMANS;

EID: 84884677843     PISSN: 16617827     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph10094261     Document Type: Review

References (85)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision, 4th ed.; American Psychiatric Association: Washington, DC, USA, 2000.
2. Blake, J.; Hoyme, H.E.; Crotwell, P.L. A brief history of autism, the autism/vaccine hypothesis and areview of the genetic basis of autism spectrum disorders. S D Med. 2013, Spec No: 58-65.
3. Siniscalco, D.; Antonucci, N. Possible use of Trichuris suis ova in autism spectrum disorders therapy. Med. Hypotheses 2013, 81, 1-4.
4. Miles, J.H.; McCathren, R.B.; Stichter, J.; Shinawi, M. Autism Spectrum Disorders. In GeneReviews™ (Internet); Pagon, R.A., Adam, M.P., Bird, T.D., Dolan, C.R., Fong, C.T., Stephens, K., Eds.; University of Washington: Seattle, WA, USA, 1993-2013.
5. Bradstreet, J.J.; Smith, S.; Baral, M.; Rossignol, D.A. Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder. Altern. Med. Rev. 2010, 15, 15-32.
6. Rossignol, D.A.; Bradstreet, J.J.; van Dyke, K.; Schneider, C.; Freedenfeld, S.H.; O'Hara, N.; Cave, S.; Buckley, J.A.; Mumper, E.A.; Frye, R.E. Hyperbaric oxygen treatment in autism spectrum disorders. Med. Gas. Res. 2012, 2, 16, doi:10.1186/2045-9912-2-16.
7. Adams, J.B.; Baral, M.; Geis, E.; Mitchell, J.; Ingram, J.; Hensley, A.; Zappia, I.; Newmark, S.; Gehn, E.; Rubin, R.A.; et al. The severity of autism is associated with toxic metal body burden and red blood cell glutathione levels. J. Toxicol. 2009, 2009, doi:10.1155/2009/532640.
8. Kaplan, G. What is new in adolescent psychiatry? Literature review and clinical implications. Adolesc. Med. State Art. Rev. 2013, 24, 29-42.
9. Lasalle, J.M. Epigenomic strategies at the interface of genetic and environmental risk factors for autism. J. Hum. Genet. 2013, 58, 396-401, doi:10.1038/jhg.2013.49.
10. Bushnell, P.J. Environmental influences and emerging mechanisms in the etiology of autism. Neurotoxicol. Teratol. 2013, 36, 1-2.
11. Cheslack-Postava, K.; Rantakokko, P.V.; Hinkka-Yli-Salomäki, S.; Surcel, H.M.; McKeague, I.W.; Kiviranta, H.A.; Sourander, A.; Brown, A.S. Maternal serum persistent organic pollutants in the Finnish Prenatal Study of Autism: A pilot study. Neurotoxicol. Teratol. 2013, 38C, 1-5.
12. Herbert, M.R. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr. Opin. Neurol. 2010, 23, 103-110.
13. Siniscalco, D.; Sapone, A.; Cirillo, A.; Giordano, C.; Maione, S.; Antonucci, N. Autism spectrum disorders: Is mesenchymal stem cell personalized therapy the future? J. Biomed. Biotechnol. 2012, 2012, doi:10.1155/2012/480289.
14. Roberts, A.L.; Lyall, K.; Hart, J.E.; Laden, F.; Just, A.C.; Bobb, J.F.; Koenen, K.C.; Ascherio, A.; Weisskopf, M.G. Pollutant exposures and autism spectrum disorder in the children of nurses' health study II participants. Environ. Health Perspect. 2013, 121, 978-984.
15. Flashner, B.M.; Russo, M.E.; Boileau, J.E.; Leong, D.W.; Gallicano, G.I. Epigenetic factors and autism spectrum disorders. Neuromol. Med. 2013, 15, 339-350.
16. Sykes, N.H.; Lamb, J.A. Autism: The quest for the genes. Expert Rev. Mol. Med. 2007, 9, 1-15.
17. Waddington, C.H. The epigenotype. Endeavor.1942, 1, 18-20.
18. Angata, T.; Fujinawa, R.; Kurimoto, A.; Nakajima, K.; Kato, M.; Takamatsu, S.; Korekane, H.; Gao, C.X.; Ohtsubo, K.; Kitazume, S.; et al. Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. Ann. N. Y. Acad. Sci. 2012, 1253, 159-169.
19. Hu, V.W. The expanding genomic landscape of autism: Discovering the "forest" beyond the "trees". Future Neurol. 2013, 8, 29-42.
20. Cox, M.; Nelson, D.R.; Lehninger, A.L. Lehninger. Principles of Biochemistry; W. H. Freeman: San Francisco, CA, USA, 2005; ISBN 0-7167-4339-6.
21. Qiu, J. Epigenetics: Unfinished symphony. Nature 2006, 441, 143-145.
22. Latham, K.E.; Sapienza, C.; Engel, N. The epigenetic lorax: Gene-environment interactions in human health. Epigenomics 2012, 4, 383-402.
23. Wong, C.C.; Meaburn, E.L.; Ronald, A.; Price, T.S.; Jeffries, A.R.; Schalkwyk, L.C.; Plomin, R.; Mill, J. Methylomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioral traits. Mol. Psychiatry 2013, in press.
24. Mamrut, S.; Harony, H.; Sood, R.; Shahar-Gold, H.; Gainer, H.; Shi, Y.J.; Barki-Harrington, L.; Wagner, S. DNA methylation of specific CpG sites in the promoter region regulates the transcription of the mouse oxytocin receptor. PLoS One 2013, 8, e56869, doi:10.1371/ journal.pone.0056869.
25. Harony, H.; Wagner, S. The contribution of oxytocin and vasopressin to mammalian social behavior: Potential role in autism spectrum disorder. Neurosignals 2010, 18, 82-97.
26. Jack, A.; Connelly, J.J.; Morris, J.P. DNA methylation of the oxytocin receptor gene predicts neural response to ambiguous social stimuli. Front. Hum. Neurosci. 2012, 6, 280, doi:10.3389/fnhum.2012.00280.
27. Beri, S.; Tonna, N.; Menozzi, G.; Bonaglia, M.C.; Sala, C.; Giorda, R. DNA methylation regulates tissue-specific expression of Shank3. J. Neurochem. 2007, 101, 1380-1391.
28. Uchino, S.; Waga, C. SHANK3 as an autism spectrum disorder-associated gene. Brain Dev. 2013, 35, 106-110.
29. Durand, C.M.; Betancur, C.; Boeckers, T.M.; Bockmann, J.; Chaste, P.; Fauchereau, F.; Nygren, G.; Rastam, M.; Gillberg, I.C.; Anckarsäter, H.; et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat. Genet. 2007, 39, 25-27.
30. Jamain, S.; Quach, H.; Betancur, C.; Råstam, M.; Colineaux, C.; Gillberg, I.C.; Soderstrom, H.; Giros, B.; Leboyer, M.; Gillberg, C.; et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat. Genet. 2003, 34, 27-29.
31. Földy, C.; Malenka, R.C.; Südhof, T.C. Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron 2013,78, 498-509.
32. Siniscalco, D.; Sapone, A.; Giordano, C.; Cirillo, A.; de Magistris, L.; Rossi, F.; Fasano, A.; Bradstreet, J.J.; Maione, S.; Antonucci, N. Cannabinoid receptor Type 2, but not Type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. J. Autism Dev. Disord. 2013, doi:10.1007/s10803-013-1824-9.
33. Melnyk, S.; Fuchs, G.J.; Schulz, E.; Lopez, M.; Kahler, S.G.; Fussell, J.J.; Bellando, J.; Pavliv, O.; Rose, S.; Seidel, L.; et al. Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism. J. Autism Dev. Disord. 2012, 42, 367-377.
34. Nguyen, A.; Rauch, T.A.; Pfeifer, G.P.; Hu, V.W. Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. FASEB J. 2010, 24, 3036-3051.
35. García-Sáez, A.J. The secrets of the Bcl-2 family. Cell. Death Differ. 2012, 19, 1733-1740.
36. Boukhtouche, F.; Vodjdani, G.; Jarvis, C.I.; Bakouche, J.; Staels, B.; Mallet, J.; Mariani, J.; Lemaigre-Dubreuil, Y.; Brugg, B. Human retinoic acid receptor-related orphan receptor alpha1 overexpression protects neurones against oxidative stress-induced apoptosis. J. Neurochem. 2006, 96, 1778-1789.
37. Hu, VW. Is retinoic acid-related orphan receptor-alpha (RORA) a target for gene-environment interactions contributing to autism? Neurotoxicology 2012, 33, 1434-1435.
38. Sarachana, T.; Xu, M.; Wu, R.C.; Hu, V.W. Sex hormones in autism: Androgens and estrogens differentially and reciprocally regulate RORA, a novel candidate gene for autism. PLoS One 2011, 6, e17116, doi:10.1371/journal.pone.0017116.
39. Gropman, A.L.; Batshaw, M.L. Epigenetics, copy number variation, and other molecular mechanisms underlying neurodevelopmental disabilities: New insights and diagnostic approaches. J. Dev. Behav. Pediatr. 2010, 31, 582-591.
40. Zhao, X.; Pak, C.; Smrt, R.D.; Jin, P. Epigenetics and Neural developmental disorders: Washington DC, September 18 and 19, 2006. Epigenetics 2007, 2, 126-134.
41. Berger, S.L. The complex language of chromatin regulation during transcription. Nature 2007, 447, 407-412.
42. Akbarian, S.; Huang, H.S. Epigenetic regulation in human brain-focus on histone lysine methylation. Biol. Psychiatry 2009, 65, 198-203.
43. Biron, V.L.; McManus, K.J.; Hu, N.; Hendzel, M.J.; Underhill, D.A. Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Dev. Biol. 2004, 276, 337-351.
44. Shulha, H.P.; Cheung, I.; Whittle, C.; Wang, J.; Virgil, D.; Lin, C.L.; Guo, Y.; Lessard, A.; Akbarian, S.; Weng, Z. Epigenetic signatures of autism: Trimethylated H3K4 landscapes in prefrontal neurons. Arch. Gen. Psychiatry 2012, 69, 314-324.
45. Adegbola, A.; Gao, H.; Sommer, S.; Browning, M. A novel mutation in JARID1C/SMCX in a patient with autism spectrum disorder (ASD). Am. J. Med. Genet. Part A 2008, 146A, 505-511.
46. Wang, H.; Duclot, F.; Liu, Y.; Wang, Z.; Kabbaj, M. Histone deacetylase inhibitors facilitate partner preference formation in female prairie voles. Nat. Neurosci. 2013, 16, 919-924.
47. Miyake, K.; Hirasawa, T.; Koide, T.; Kubota, T. Epigenetics in autism and other neurodevelopmental diseases. Adv. Exp. Med. Biol. 2012, 724, 91-98.
48. St-Hilaire, S.; Ezike, V.O.; Stryhn, H.; Thomas, M.A. An ecological study on childhood autism. Int. J. Health Geogr. 2012, 11, 44, doi:10.1186/1476-072X-11-44.
49. Volk, H.E.; Lurmann, F.; Penfold, B.; Hertz-Picciotto, I.; McConnell, R. Traffic-related air pollution, particulate matter, and autism. JAMA Psychiatry 2013, 70, 71-77.
50. Rasalam, A.D.; Hailey, H.; Williams, J.H.; Moore, S.J.; Turnpenny, P.D.; Lloyd, D.J.; Dean, J.C. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev. Med. Child. Neurol. 2005, 47, 551-555.
51. Wolstenholme, J.T.; Edwards, M.; Shetty, S.R.; Gatewood, J.D.; Taylor, J.A.; Rissman, E.F.; Connelly, J.J. Gestational exposure to bisphenol a produces transgenerational changes in behaviors and gene expression. Endocrinology 2012, 153, 3828-3838.
52. Veenema, A.H.; Neumann, I.D. Central vasopressin and oxytocin release: Regulation of complex social behaviours. Prog. Brain Res. 2008, 170, 261-276.
53. Lukas, M.; Neumann, I.D. Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders. Behav. Brain Res. 2012, doi:10.1016/j.bbr.2012.08.011.
54. Murakami, G.; Hunter, R.G.; Fontaine, C.; Ribeiro, A.; Pfaff, D. Relationships among estrogen receptor, oxytocin and vasopressin gene expression and social interaction in male mice. Eur. J. Neurosci. 2011, 34, 469-477.
55. Kumsta, R.; Hummel, E.; Chen, F.S.; Heinrichs, M. Epigenetic regulation of the oxytocin receptor gene: Implications for behavioral neuroscience. Front. Neurosci. 2013, 7, 83, doi:10.3389/ fnins.2013.00083.
56. Ma, W.J.; Hashii, M.; Munesue, T.; Hayashi, K.; Yagi, K.; Yamagishi, M.; Higashida, H.; Yokoyama, S. Non-synonymous single-nucleotide variations of the human oxytocin receptor gene and autism spectrum disorders: A case-control study in a Japanese population and functional analysis. Mol. Autism. 2013, 4, 22, doi:10.1186/2040-2392-4-22.
57. Viberg, H.; Mundy, W.; Eriksson, P. Neonatal exposure to decabrominated diphenyl ether (PBDE 209) results in changes in BDNF, CaMKII and GAP-43, biochemical substrates of neuronal survival, growth, and synaptogenesis. Neurotoxicology 2008, 29, 152-159.
58. Kim, S.M.; Han, D.H.; Lyoo, H.S.; Min, K.J.; Kim, K.H.; Renshaw, P. Exposure to environmental toxins in mothers of children with autism spectrum disorder. Psychiatry Investig. 2010, 7, 122-127.
59. Ricci, S.; Businaro, R.; Ippoliti, F.; Lo Vasco, V.R.; Massoni, F.; Onofri, E.; Troili, G.M.; Pontecorvi, V.; Morelli, M.; Rapp Ricciardi, M.; et al. Altered cytokine and BDNF levels in Autism spectrum disorder. Neurotox. Res. 2013, doi:10.1007/s12640-013-9393-4.
60. Siniscalco, D.; Giordano, C.; Rossi, F.; Maione, S.; de Novellis, V. Role of neurotrophins in neuropathic pain. Curr. Neuropharmacol. 2011, 9, 523-529.
61. Garcia, K.L.; Yu, G.; Nicolini, C.; Michalski, B.; Garzon, D.J.; Chiu, V.S.; Tongiorgi, E.; Szatmari, P.; Fahnestock, M. Altered balance of proteolytic isoforms of pro-brain-derived neurotrophic factor in autism. J. Neuropathol. Exp. Neurol. 2012, 71, 289-297.
62. Naviaux, R.K.; Zolkipli, Z.; Wang, L.; Nakayama, T.; Naviaux, J.C.; Le, T.P.; Schuchbauer, M.A.; Rogac, M.; Tang, Q.; Dugan, L.L.; et al. Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model. PLoS One 2013, 8, e57380, doi:10.1371/journal.pone.0057380.
63. Zikopoulos, B.; Barbas, H. Changes in prefrontal axons may disrupt the network in autism. J. Neurosci. 2010, 30, 14595-14609.
64. Sanders, B.K. Flowers for Algernon: Steroid dysgenesis, epigenetics and brain disorders. Pharmacol. Rep. 2012, 64, 1285-1290.
65. Whitehouse, A.J.; Holt, B.J.; Serralha, M.; Holt, P.G.; Hart, P.H.; Kusel, M.M. Maternal vitamin D levels and the autism phenotype among offspring. J. Autism Dev. Disord. 2013, 43, doi:10.1007/s10803-012-1676-8.
66. Grant, W.B.; Soles, C.M. Epidemiologic evidence supporting the role of maternal vitamin D deficiency as a risk factor for the development of infantile autism. Derm. Endocrinol. 2009, 1, 223-228.
67. Sundar, I.K.; Rahman, I. Vitamin d and susceptibility of chronic lung diseases: Role of epigenetics. Front. Pharmacol. 2011, 2, 50, doi:10.3389/fphar.2011.00050.
68. James, S.J.; Melnyk, S.; Jernigan, S.; Cleves, M.A.; Halsted, C.H.; Wong, D.H.; Cutler, P.; Bock, K.; Boris, M.; Bradstreet, J.J.; et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B, 947-956.
69. Trivedi, M.S.; Deth, R.C. Role of a redox-based methylation switch in mRNA life cycle (pre-and post-transcriptional maturation) and protein turnover: Implications in neurological disorders. Front. Neurosci. 2012, 6, 92, doi:10.3389/fnins.2012.00092.
70. Siniscalco, D.; Bradstreet, J.J.; Antonucci, N. Therapeutic role of hematopoietic stem cells in autism spectrum disorder-related inflammation. Front. Immunol. 2013, 4, 140, doi:10.3389/ fimmu.2013.00140.
71. Deth, R.; Muratore, C.; Benzecry, J.; Power-Charnitsky, V.A.; Waly, M. How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. Neurotoxicology 2008, 29, 190-201.
72. Gos, M. Epigenetic mechanisms of gene expression regulation in neurological diseases. Acta Neurobiol. Exp. (Wars) 2013, 73, 19-37.
73. Lilja, T.; Wallenborg, K.; Björkman, K.; Albåge, M.; Eriksson, M.; Lagercrantz, H.; Rohdin, M.; Hermanson, O. Novel alterations in the epigenetic signature of MeCP2-targeted promoters in lymphocytes of Rett syndrome patients. Epigenetics 2013, 8, 246-251.
74. Wijetunge, L.S.; Chattarji, S.; Wyllie, D.J.; Kind, P.C. Fragile X syndrome: From targets to treatments. Neuropharmacology 2013, 68, 83-96.
75. Healy, A.; Rush, R.; Ocain, T. Fragile X syndrome: An update on developing treatment modalities. ACS Chem. Neurosci. 2011, 2, 402-410.
76. He, F.; Todd, P.K. Epigenetics in nucleotide repeat expansion disorders. Semin. Neurol. 2011, 31, 470-483.
77. Coffee, B.; Zhang, F.; Ceman, S.; Warren, S.T.; Reines, D. Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome. Am. J. Hum. Genet. 2002, 71, 923-932.
78. Kwasnicka-Crawford, D.A.; Roberts, W.; Scherer, S.W. Characterization of an autism-associated segmental maternal heterodisomy of the chromosome 15q11-13 region. J. Autism Dev. Disord. 2007, 37, 694-702.
79. Schanen, N.C. Epigenetics of autism spectrum disorders. Hum. Mol. Genet. 2006, 15, R138-R150, doi: 10.1093/hmg/ddl213.
80. Hogart, A.; Leung, K.N.; Wang, N.J.; Wu, D.J.; Driscoll, J.; Vallero, R.O.; Schanen, N.C.; LaSalle, J.M. Chromosome 15q11-13 duplication syndrome brain reveals epigenetic alterations in gene expression not predicted from copy number. J. Med. Genet. 2009, 46, 86-93.
81. Hogart, A.; Nagarajan, R.P.; Patzel, K.A.; Yasui, D.H.; Lasalle, J.M. 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Hum. Mol. Genet. 2007, 16, 691-703.
82. Szyf, M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 243-263.
83. Millan, M.J. An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy. Neuropharmacology 2013, 68, 2-82.
84. Bashir, Q.; William, B.M.; Garcia-Manero, G.; de Lima, M. Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. Rev. Bras. Hematol. Hemoter. 2013, 35, 126-133.
85. Harrison, I.F.; Dexter, D.T. Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease? Pharmacol. Ther. 2013, doi: 10.1016/j.pharmthera.2013.05.010.